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Background: Chloroquine and primaquine are the first-line treatment recommended by World Health Organization
for malaria caused by Plasmodium vivax. Since the problem of counterfeit or substandard anti-malarials is well
established all over the world, the development of rapid and reliable methods for quality control analysis of
these drugs is essential. Thus, the aim of this study was to develop and validate a novel UPLC-DAD method
for simultaneously quantifying chloroquine and primaquine in tablet formulations.
Methods: The UPLC separation was carried out using a Hypersil C18 column (50 × 2.1 mm id; 1.9 μm particle size)
and a mobile phase composed of acetonitrile (A) and 0.1% aqueous triethylamine, pH 3.0 adjusted with phosphoric
acid (B), at a flow rate 0.6 mL/min. Gradient elution was employed. UV detection was performed at 260 nm. UPLC
method was fully validated and the results were compared to a conventional HPLC-DAD method for the analysis of
chloroquine and primaquine in tablet formulations.
Results: UPLC method was shown to be linear (r2 > 0.99), precise (CV < 2.0%), accurate (recovery rates from 98.11 to
99.83%), specific, and robust. No significant differences were observed between the chloroquine and primaquine
contents obtained by UPLC and HPLC methods. However, UPLC method promoted faster analyses, better
chromatographic performance and lower solvent consumption.
Conclusions: The developed UPLC method was shown to be a rapid and suitable technique to quantify
chloroquine and primaquine in pharmaceutical preparations and may be successfully employed for quality
control analysis.
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Malaria is the world’s most important parasitic infection,
ranking among the major health and developmental
challenges for the poor countries of the world [1]. Glo-
bally, an estimated 3.4 billion people are at risk of mal-
aria. Malaria may be caused by five species of parasites,
and Plasmodium falciparum and Plasmodium vivax are
the most important. Plasmodium falciparum malaria is
the most deadly form, while malaria caused by P. vivax
has a wider distribution, since it is able to develop in the
Anopheles mosquito vector at lower temperatures, and* Correspondence: isaccesar@bol.com.br
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unless otherwise stated.to survive at higher altitudes and in cooler climates. It also
has a dormant liver stage that enables it to survive during
periods when Anopheles mosquitoes are not present to
continue transmission [1,2].
The objective of treating malaria caused by P. vivax is
to cure both the blood stage and the liver stage infec-
tions and, thereby, prevent both recrudescence and
relapse, respectively. According to the World Health
Organization, treatment of P. vivax should include an
effective schizontocidal medicine, such as chloroquine,
combined with a 14-day course of primaquine to prevent
relapse (Figure 1) [3,4].
The use of counterfeit and/or substandard anti-malarial
drugs can cause increased morbidity and mortality,
adverse effects due to excessive dose or the presencel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chemical structures of chloroquine (CHLO) and
primaquine (PRIM).
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taminants, and the selection of resistant parasites with sub-
therapeutic amounts of active ingredient [5]. In addition,
treatment failure may be improperly attributed to drug re-
sistance when the product does not meet the qualitative
and quantitative requirements [6]. Hence, quality control
of anti-malarial pharmaceutical preparations marketed
nowadays may help to assure treatment efficacy and avoid
development of resistance to anti-malarial drugs [7].
Ultra-performance liquid chromatography (UPLC) is a
novel advance in rapid, sensitive and high-resolution li-
quid chromatography [8]. An ultra-high pressure system
allows the use of small particle-packed columns with
small diameter. The particles are designed to be able to
resist high back pressures, in contrast with conventional
liquid chromatography [9]. Therefore, UPLC has signifi-
cant theoretical advantages in speed, resolution and
sensitivity of analysis, especially in time saving and solvent
consumption [10,11].
Some papers have described the quantitation of chloro-
quine or primaquine in pharmaceutical formulations,
using liquid chromatography coupled to ultraviolet [12,13]
or mass spectrometric detection [14]. Dwivedi et al. [15]
described the simultaneous quantitation of chloroquine,
primaquine and bulaquine by a HPLC method with a
long run time of 20 min. However, there are no re-
ported methods regarding the simultaneous quantitation of
chloroquine and primaquine using UPLC. Hence, the aim
of this study was to develop and validate a novel UPLC-
DAD method for simultaneously quantifying chloroquine
and primaquine. The validated method was compared to a
conventional HPLC-DAD method for the analysis of these
anti-malarial drugs in tablet formulations.
Methods
Samples and chemicals
Chloroquine diphosphate and primaquine diphosphate
reference standards were purchased from Farmacopeia
Brasileira (Brasília, DF, Brazil). Chloroquine diphosphate
tablets containing 150 mg chloroquine base and prima-
quine diphosphate tablets containing 15 mg primaquine
base were produced by Farmanquinhos/Fundação Oswaldo
Cruz (Rio de Janiero, RJ, Brazil). Ultra-pure water wasobtained from a Millipore system (Bedford, MA, USA).
Acetonitrile and methanol (HPLC grade) were purchased
from Tedia (Fairfield, OH, USA) and phosphoric acid
and triethylamine (analytical grade) were from JT Baker
(Phillipsburg, NJ, USA).
HPLC analytical conditions
The HPLC analyses were carried out on an Acella sys-
tem from Thermo Scientific (Waltham, MA, USA), com-
posed of quaternary pump, autosampler and diode array
detector (DAD). The column was an ACE C18 (100 ×
4.6 mm id; 5 μm particle size) from ACT (Aberdeen,
Scotland), maintained at 25°C. UV detection was per-
formed at 260 nm and injection volume was 10 μl. The
mobile phase was composed of acetonitrile (A) and
0.1% aqueous triethylamine, pH 3.0 adjusted with phos-
phoric acid (B), at a flow rate 1 mL/min. The gradient elu-
tion programme was 10% A from 0–1.9 min, 10-40% A
from 1.9-2.0 min and 40% A from 2.0-3.3 min. For
column re-equilibration, 10% A was maintained from
3.3-5.00 min.
UPLC analytical conditions
The analytical conditions employed for the UPLC method
were adapted from the HPLC method previously devel-
oped and used for routine analyses. The UPLC analyses
were carried out on an Acella system from Thermo Scientific
(Waltham, MA, USA), composed of quaternary pump,
autosampler and DAD. The column was a Hypersil C18
(50 × 2.1 mm id; 1.9 μm particle size) from Thermo
Scientific (Waltham, MA, USA), maintained at 25°C. UV
detection was performed at 260 nm. UV spectra from 200
to 400 nm were on line recorded for peak identification.
The injection volume was 7.0 μl. The mobile phase was
composed of acetonitrile (A) and 0.1% aqueous triethyla-
mine, pH 3.0 adjusted with phosphoric acid (B), at a flow
rate 0.6 mL/min. The separation of chloroquine and
primaquine was evaluated in different proportions of these
solvents and, for each condition, retention time and reso-
lution (R) were calculated. The optimized condition was
achieved using a gradient elution programme: 10% A from
0–0.45 min, 10-40% A from 0.45-0.47 min and 40% A
from 0.47-1.30 min. For column re-equilibration, 10% A
was maintained from 1.30-4.00 min.
Preparation of solutions
Chloroquine and primaquine standard solution
Approximately 20.16 mg of chloroquine diphosphate ref-
erence standard (corresponding to 12.50 mg of chloro-
quine base) were accurately weighed and transferred to a
25-ml volumetric flask. Twenty mL of methanol and 0.1%
aqueous triethylamine pH 3.0 (1:1) were added to ensure
complete dissolution and solution was diluted to volume
using the same solvent. Approximately 21.95 mg of
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ing to 12.50 mg of primaquine base) were accurately
weighed and transferred to a different 25-ml volumetric
flask. Twenty mL of methanol and 0.1% aqueous triethyla-
mine pH 3.0 (1:1) were added to ensure complete dis-
solution and solution was diluted to volume using the
same solvent. Then, aliquots of 3 mL chloroquine stock
solution and 2 mL primaquine stock solution were
transferred to a 10-ml volumetric flask. This solution was
diluted to volume, obtaining final concentrations of
0.15 mg/mL chloroquine and 0.10 mg/mL primaquine.
Chloroquine and primaquine sample solution
Chloroquine and primaquine tablets were previously weighed
and finely powdered. An accurately weighed portion of
chloroquine tablet powder, equivalent to about 12.50 mg
chloroquine base, was transferred to a 25-ml volumetric
flask followed by the dissolution with methanol and 0.1%
aqueous triethylamine pH 3.0 (1:1). In parallel, an accur-
ately weighed portion of primaquine tablet powder,
equivalent to about 10.00 mg primaquine base, was
transferred to a 50-ml volumetric flask followed by the
dissolution with methanol and 0.1% aqueous triethylamine
pH 3.0 (1:1). Then, aliquots of 3 mL chloroquine solution
and 5 mL primaquine solution were transferred to a 10-ml
volumetric flask. This solution was diluted to volume,
obtaining final concentrations of 0.15 mg/mL chloroquine
and 0.10 mg/mL primaquine.
Validation
Both HPLC and UPLC methods were fully validated, ac-
cording to International Conference on Harmonization
Guideline - validation of analytical procedures [16]. All
the described parameters were evaluated for both methods
and the obtained results were compared.
Linearity
Standard solutions containing 0.30 mg/mL of chloro-
quine and 0.20 mg/mL of primaquine were prepared, in
triplicate. Aliquots of these solutions were diluted in
methanol and 0.1% aqueous triethylamine pH 3.0 (1:1)
to five different concentrations, corresponding to 0.09,
0.12, 0.15, 0.18, and 0.21 mg/mL of chloroquine and 0.06,
0.08, 0.10, 0.12, and 0.14 mg/mL of primaquine. Linear
ranges corresponded from 60% to 140% of test concentra-
tion for each drug. Calibration curves for concentration
versus peak area were plotted for each compound and the
obtained data were subjected to regression analysis using
the least squares method.
Precision
The intra-day precision was evaluated by analysing six
samples (n = 6), at 100% of the test concentration (0.15 mg/
mL of chloroquine and 0.10 mg/mL of primaquine).Similarly, the inter-day precision was evaluated in two
consecutive days (n = 12). Chloroquine and primaquine
concentrations were determined and the coefficient of
variation (CV%) were calculated.
Accuracy
Recovery was investigated by means of a standard addition
experiment. Different volumes of standard solutions con-
taining 0.30 mg/mL of chloroquine and 0.20 mg/mL of
primaquine were added to a sample solution prepared
with chloroquine and primaquine tablets. These solutions
were further diluted with methanol and 0.1% aqueous
triethylamine pH 3.0 (1:1), obtaining three levels: 75, 100
and 125% of the label claim. At each level, samples were
prepared in triplicate and the recovery percentage was
determined.
Specificity
Spectral purities of chloroquine and primaquine chroma-
tographic peaks were evaluated using the UV spectra re-
corded by the DAD to evaluate possible interfering peaks.
This analysis was performed employing both standard and
sample solutions, at test concentration (0.15 mg/mL of
chloroquine and 0.10 mg/mL of primaquine).
Robustness
Chloroquine and primaquine sample solutions (n = 4)
were prepared and analysed under the established condi-
tions and by variation of the following analytical parame-
ters: acetonitrile concentration in mobile phase (±2%),
mobile phase pH (±0.3) and column temperature (±2°C).
Chloroquine and primaquine contents were determined
for each condition and the obtained data were submitted
to statistical analysis (ANOVA test). Statistical signifi-
cance was set at P <0.05.
Detection and quantitation limits
Detection and quantitation limits of both methods were
calculated based on the ratio of standard deviation of
response and slope of calibration curves. For detection
limit, a relation of 3.3 was considered, whereas for quan-
titation limit the relation was 10.
Analysis of chloroquine and primaquine tablets by UPLC
and HPLC methods
Tablet formulations (Farmanguinhos, RJ, Brazil), contain-
ing 150 mg chloroquine base and 15 mg primaquine base
were assayed using both validated UPLC and HPLC
methods. Before the analysis, 20 chloroquine tablets and
20 primaquine tablets were weighed and finely powdered.
An accurately weighed portion of the powders, equivalent
to about 12.50 mg chloroquine base and 10.00 mg of
primaquine were employed to prepare solutions, as de-
scribed in “Chloroquine and primaquine sample solution”.
Figure 2 Chromatograms obtained by UPLC (full line) and HPLC (dotted line) for analysis of chloroquine (CHLO) and primaquine
(PRIM) in tablet formulations.
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consecutive days. The contents of chloroquine and
primaquine in tablets (% of labeled amount) and co-
efficient of variation (CV%) were determined for each
method. The results were statistically compared using
Student’s t-test. Statistical significance was set at P <0.05.
In addition, UPLC and HPLC methods were also com-
pared regarding analysis time, tailing factor and solvent
consumption.Figure 3 Calibration curves of (A) chloroquine and (B) primaquine obResults
Method development
Chromatographic parameters employed for the UPLC method
development were initially adapted from HPLC method
already used for routine analysis in our laboratory. The
chromatographic parameters were firstly evaluated using
C18 column and isocratic elution with a mobile phase com-
posed of 60% organic solvent. Under these conditions, the
retention factor obtained for chloroquine was considerablytained by HPLC and UPLC methods.
Table 1 Precision and accuracy data for chloroquine and




Chloroquine Primaquine Chloroquine Primaquine
Precision
(CV%)
Intra-day 1.10 1.04 1.10 0.31
Inter-day 1.49 1.05 1.59 1.21
Accuracy
(recovery %)
99.22 99.67 99.83 98.11
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in mobile phase increased the retention of primaquine
peak, leading to a long run time, besides causing peak
tailing. The use of gradient elution promoted adequate re-
tention times and peak shapes for both anti-malarial drugs.
Acetonitrile instead of methanol showed to be a better
choice to assure the adequate separation of peaks. Finally,
different pH values of mobile phase were evaluated and
better peak symmetries were obtained at pH 3.0. Under
these optimized conditions, chloroquine and primaquine
peaks eluted at 1.0 and 1.3 min, respectively (Figure 2).
Validation
Linearity
Linear correlation was found between the peak areas and
the concentrations of chloroquine and primaquine, in the
assayed range, for both HPLC and UPLC methods, using
the least squares method. A random pattern of the regres-
sion residues was found and no significant deviation of
linearity was detected in the assayed range. The regression
analysis curves are showed in Figure 3. The regression
coefficient (r2) values obtained, higher to 0.99 to both
compounds, attested the linearity of the methods.
Precision and accuracy
RSD and recovery values obtained for chloroquine and
primaquine by HPLC and UPLC methods are demon-
strated in Table 1. The obtained CV% values, lower thanTable 2 Robustness results for chloroquine and primaquine o
Conditions Chloroquine
Mean content (%) R.S.D. (%) Retenti
Nominal* 99.59 0.90 2.58
Acetonitile concentration 8-38% 99.92 0.77 2.60
Acetonitile concentration 12-42% 99.49 1.10 2.56
Mobile phase pH 2.7 99.80 1.46 2.58
Mobile phase pH 3.3 100.06 1.65 2.58
Temperature 23°C 99.31 0.67 2.60
Temperature 27°C 99.63 1.13 2.59
*Acetonitrile concentration in gradient 10-40%, mobile phase pH 3.0, temperature 22.0% [17], assure the HPLC and UPLC method precision.
In addition, the employed standard addition experiment
demonstrated that both methods were accurate for chloro-
quine and primaquine analysis, since recovery rates were
within the predetermined range of 98.0-102.2% [18].
Specificity
No interfering peak was found in chromatograms during
the optimization step and validation process. Peak pu-
rities higher than 99.0% were obtained using DAD for
chloroquine and primaquine, since the UV spectra of the
peaks obtained with sample solutions were superimpos-
able to the spectra of the peaks obtained with reference
standards in HPLC and UPLC methods. It demonstrated
that other compounds did not co-elute with the main
peaks, attesting the specificity of both methods.
Robustness
Robustness results obtained for chloroquine and primaquine
after variation of analytical parameters are demonstrated in
Tables 2 and 3 for HPLC and UPLC methods, respectively.
Statistical analysis showed no significant difference between
results obtained employing the analytical conditions estab-
lished for the method and those obtained in the experiments
in which variations of some parameters were introduced for
chloroquine and primaquine. Thus, HPLC and UPLC
methods showed to be robust regarding chloroquine and
primaquine contents for changes in acetonitrile concentra-
tion in mobile phase during gradient elution (±2%), mobile
phase pH in the range of 2.7 to 3.3 and column temperature
from 23°C to 27°C.
Detection and quantitation limits
Using the described HPLC method, detection limits were
0.01 and 0.003 mg/mL for chloroquine and primaquine,
respectively. Quantitation limits of 0.03 and 0.010 mg/mL
were found for chloroquine and primaquine. Using the
developed UPLC method, same values were found for
chloroquine: 0.01 and 0.03 mg/mL for detection and
quantitation limits, respectively. For primaquine, detectionbtained by HPLC method
Primaquine









Table 3 Robustness results for chloroquine and primaquine obtained by UPLC method
Conditions Chloroquine Primaquine
Mean content (%) R.S.D. (%) Retention time (min) Mean content (%) R.S.D. (%) Retention time (min)
Nominal* 99.65 0.77 1.00 99.87 0.36 1.31
Acetonitile concentration 8-38% 98.72 1.22 1.08 98.05 1.00 1.45
Acetonitile concentration 12-42% 98.36 1.04 0.73 98.86 1.15 1.27
Mobile phase pH 2.7 99.02 0.92 1.01 98.69 0.50 1.28
Mobile phase pH 3.3 100.53 1.15 1.02 99.12 0.88 1.34
Temperature 23°C 99.97 1.17 1.01 99.11 1.07 1.33
Temperature 27°C 100.42 0.99 0.99 99.26 0.74 1.31
*Acetonitrile concentration in gradient 10-40%, mobile phase pH 3.0, temperature 25°C.
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limit was 0.022 mg/mL. The low values of detection and
quantitation limits demonstrated adequate sensitivity of
both methods.
Comparison of UPLC and HPLC methods for analysis of
chloroquine and primaquine in tablets
Samples of chloroquine and primaquine tablet formula-
tions were analysed using both HPLC and UPLC validated
methods. The results obtained are showed in Table 4. All
analysed samples presented chloroquine and primaquine
contents very close to the labeled amount. Student’s t-test
was employed to compare the mean contents obtained by
HPLC and UPLC methods. No significant differences were
observed between the results, demonstrating that both
chromatographic methods were equivalents regarding
chloroquine and primaquine contents. Retention time re-
peatability and tailing factor of chromatographic peaks
were similar for both techniques. In addition, UPLC and
HPLC methods complied with all required validation
parameters and presented resolution higher than 1.5
between chloroquine and primaquine peaks [19].
However, UPLC method demonstrated lower retention
times for the analyte peaks, as showed in Figure 2,
allowing high throughput analysis. Total run time of
UPLC method (1.5 min) was half of that obtained byTable 4 Mean contents of chloroquine and primaquine
bases in tablet formulations obtained by UPLC and HPLC
methods (n = 12)
Results UPLC HPLC
Chloroquine Primaquine Chloroquine Primaquine
Content (%) 99.15 99.22 99.99 98.79
Content
(mg/tablet)
148.73 14.88 149.99 14.82
Standard
deviation
1.48 1.04 1.59 1.11
CV (%) 1.49 1.05 1.59 1.12conventional HPLC method (3.0 min). In spite of a
longer time for column re-equilibration being needed
for UPLC method, the total run time was faster, and
mobile phase flow rate of UPLC (0.6 mL/min) was lower
than HPLC method (1.0 mL/min). These factors pro-
moted a considerably low solvent consumption, reducing
the cost of analysis and demonstrating a greener chroma-
tographic approach for routine analysis.
The developed method offers the advantage over those
previously reported using conventional liquid chro-
matography [13-15] showing a faster chromatographic
total run time and better chromatographic perform-
ance. Since a high number of samples are needed for
quality control analysis, the very fast UPLC separation
combined with an adequate efficiency described in this
work allows the application of the method for routine
analysis.
In addition, the development of simple and reliable
methods is essential for qualitative and quantitative de-
termination of anti-malarial drugs, since the problem of
counterfeit or substandard anti-malarials is well estab-
lished all over the world. The adequate quality control of
the pharmaceutical preparations marketed nowadays by
means of rapid methods is an important tool to assure
the treatment efficacy with anti-malarial drugs.
Conclusions
This study was the first report of simultaneous quantita-
tion of chloroquine and primaquine by UPLC-DAD
method. The developed method was shown to be a suit-
able technique to quantify these anti-malarials in
pharmaceutical preparations and may be successfully
employed for quality control analysis. Compared to a
conventional liquid chromatography method, UPLC pro-
moted lower retention times and better chromatographic
performance, leading to shortening of analysis time and
great savings in solvent consumption. Chloroquine and
primaquine tablets analysed by the validated method
showed adequate quality and drug contents in agree-
ment with the labeled amounts.
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